Antibody

Conference speaker
#Antibody #Antisense Oligonucleotides (ASOs) #Duchenne muscular dystrophy #Sapreme Therapeutics

Sapreme shares “unprecedented” preclinical data for Duchenne candidate

Sapreme Therapeutics has shared new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US.  SPM-2551 is intended to restore dystrophin to more than 15% of normal levels –… Read More

#News

Heavy-chain-only antibody
#Antibody #Cancer Research UK #KisoJi Biotechnology #Oncology #Phase I trial

First patient receives novel heavy-chain-only antibody

Cancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours.  The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody.  TROP2 is a transmembrane glycoprotein involved in… Read More

#Cancer Research #News

Monoclonal antibody
#Antibody #iBio #Obesity #Preclinical development #Weight loss

Twice-yearly antibody shows strong therapeutic potential for weight-loss

iBio has announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate supported by preclinical data.  The findings will be presented during an oral session at ObesityWeek 2025, taking place 4-7 November in Atlanta, USA. … Read More

#News #Trending News

#AI #Antibody #Drug discovery #GPCRs

Abalone Bio talks opportunities for GPCR targets  

DDW Editor Reece Armstrong speaks to Richard Yu, CEO and Co-Founder of Abalone Bio about the company’s efforts to develop antibody antagonists for GPCR targets.  RA: What have been the biggest challenges of developing GPCR therapeutics?  RY: The number one challenge is specificity, and it plays out in a couple of… Read More

#Exclusive Content

#Antibody #Genetics

FairJourney Biologics appoints Dr Werner Lanthaler as CEO

Biotechnology company FairJourney Biologics has appointed Dr Werner Lanthaler as Chief Executive Officer (CEO), the company has announced.   Lanthaler has forged an extensive career in the biopharmaceutical industry, driving innovation, transformation and sustainable growth. Lanthaler served as CEO of Evotec SE for 15 years, where he… Read More

#News

Molecular,Model,Of,Antibody
#Antibody #Clinical trials #Haematology #Harvard Medical School #ITP #Monoclonal antibodies #Platelet biology #Takeda

Mezagitamab and the future of ITP treatment

The International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress took place in Washington DC from 21-25 June 2025. At this event, Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody (mAb), in patients with persistent or chronic primary immune thrombocytopenia… Read More

#Exclusive Content

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Antibody #Gene therapy #Neuroscience #Tau protein #Voyager Therapeutics

Anti-tau antibody and gene therapy show potential in Alzheimer’s

A single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in preclinical studies.  Voyager Therapeutics will share the new data from its two preclinical programmes for Alzheimer’s disease (AD) at the 2025 International… Read More

#News

Test for KRAS mutation
#Antibody #Combination therapy #KRAS #Oncology #University of California San Francisco

Precision drug, antibody and radiation therapy kills tumours

Scientists have found a way to combine a precision drug therapy with an antibody and radiation to eliminate tumours without causing side effects.  “This is a one-two punch,” said Charly Craik, Professor of Pharmaceutical Chemistry at University of California, San Francisco (UCSF) and co-senior author of the… Read More

#News #Trending News

#Antibody #Antibody libraries #Drug development #Drug discovery #Monoclonal antibodies

A pioneering approach to biotherapeutic antibody discovery 

This is a paid-for advertorial by BIO-RAD. Immunotherapy has revolutionised cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology such as phage display have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen. … Read More

#Exclusive Content

Antibodies attack Covid-19
#Antibody #Covid-19 #Icahn School of Medicine #Immunology / Virology & Vaccines #Nanobodies #Virus mutation

Antibody platform overcomes mutational escape in Covid-19

Scientists have developed a unique antibody platform to tackle the challenges of treating rapidly evolving viruses like SARS-CoV-2 due to their ability to mutate and evade therapies. Their findings introduce the Adaptive Multi-Epitope Targeting and Avidity-Enhanced (AMETA) Nanobody Platform. Dr Yi Shi, Associate Professor… Read More

#Editor's Choice #News

Monoclonal antibody
#Antibody #Biotherapeutics #Therapeutic Antibodies #Tumour biology

Tumour infiltrating B cells are a source of new targets and therapeutics  

Recent research is shedding light on the crucial role of B cells in the fight against cancer, opening exciting new avenues for therapeutic development, according to Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics.  Cancer immunotherapies have been raising the bar for standard of care in oncology for more than… Read More

#Exclusive Content

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

One week to go: Discover next-generation antibody production

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

Learn how to produce high-affinity & specificity rabbit mAbs

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

Next-gen antibody discovery: Leveraging DNA immunisation

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery #Webinar

New webinar: Next-generation antibody discovery

Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Join DDW on 9 September 3PM BST to find out how Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with their proprietary single B-cell cloning technique, paving the way for… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

Antibodies
#Antibodies #Antibody #Antibody discovery workflow #Drug discovery

Next-gen antibody discovery: Leveraging DNA immunisation and single B-cell cloning for high-affinity & specificity rabbit mAbs

Watch this engaging and informative webinar on Fujifilm Wako’s groundbreaking advancements in rabbit monoclonal antibody discovery. Traditional hybridoma technology has long struggled with inefficiencies, especially in producing rabbit monoclonal antibodies. Fujifilm Wako has surmounted these challenges by integrating DNA immunisation with its proprietary single B-cell cloning technique, paving the way… Read More

Webinar date:
Supported by Fujifilm Wako
#Webinars